Document is current

Article History

Accepted: 8 May 2024

First Online: 12 June 2024

Competing interests

: G.M.B. discloses the following financial and professional collaborations: Takeda Oncology — sponsored research agreement; Olink Proteomics — sponsored research agreement; Novartis — scientific advisory board, speaker; Nektar Therapeutics — scientific advisory board, steering committee; Palleon Pharmaceuticals — sponsored research agreement; InterVenn Biosciences — sponsored research agreement, scientific advisory board; Merck — scientific advisory board, consulting; Iovance — scientific advisory board; Ankyra Therapeutics — scientific advisory board, equity. A.P. has held equity in C2i Genomics, XGenomes, Cadex, Vionix and Parithera. In the past 36 months, she has served as an adviser/consultant for Eli Lilly, Mirati, Pfizer, Inivata, Biofidelity, Checkmate Pharmaceuticals, Foundation Medicine Inc., Guardant, AbbVie, Bayer, Delcath, Taiho, CVS, Value Analytics Lab, Seagen, Saga, AstraZeneca, Scare Inc., Illumina, Taiho, Hookipa, Kahar Medical, Xilio Therapeutics, Sirtex, Takeda and Science For America. She receives fees from Up to Date. She has received travel fees from Karkinos Healthcare. She has been on the DSMC for a Roche study and on the Steering Committee for Exilixis. She has received research funding to the Institution from PureTech, PMV Pharmaceuticals, Plexxicon, Takeda, Bristol Myers Squibb, Mirati, Novartis, Erasca, Genentech, Daiichi Sankyo, Syndax, Revolution Medicine and Parthenon. D.L. has received honorarium (invited speaker/travel fees) from Genentech, Inc., and is on the scientific advisory board for Oncovalent Therapeutics. A.M.H., A.D., K.S.-D. and S.C. declare no competing interests.